Comparative Pharmacology
Head-to-head clinical analysis: IRON DEXTRAN versus TRIFERIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IRON DEXTRAN versus TRIFERIC.
IRON DEXTRAN vs TRIFERIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron dextran is a colloidal solution of ferric oxyhydroxide complexed with dextran, which provides a source of iron for hemoglobin synthesis. After intramuscular or intravenous administration, the iron-dextran complex is taken up by the reticuloendothelial system, where iron is released and bound to transferrin for erythropoiesis.
Triferic (ferric pyrophosphate citrate) is an iron replacement agent that delivers iron directly to transferrin via the sodium-dependent phosphate transporter, bypassing the reticuloendothelial system, thereby increasing iron availability for erythropoiesis without increasing ferritin levels.
IM or IV: Calculate total iron deficit using formula: Body weight (kg) × (target Hb - actual Hb) × 0.24 + 500 mg (for iron stores). Administer as single IV infusion or daily IM doses up to 2 mL (100 mg) per day. IV infusion: Dilute in 0.9% NaCl and infuse over 1-6 hours; test dose of 25 mg recommended.
For iron deficiency anemia: 1 tablet (30 mg elemental iron as ferric pyrophosphate citrate) twice daily, 30 minutes before meals, administered orally.
None Documented
None Documented
The terminal elimination half-life is approximately 5-6 hours for the iron-dextran complex, but the iron released from the complex has a half-life of 2-3 days due to incorporation into erythrocytes and storage pools.
The terminal elimination half-life of ferric carboxymaltose is approximately 7-12 hours for the iron-carbohydrate complex. However, the clinical context involves redistribution of iron to stores and erythron, with a functional half-life of about 14-21 days for iron utilization.
Iron dextran is primarily excreted via the reticuloendothelial system; iron is incorporated into hemoglobin and stored as ferritin/ hemosiderin. Renal excretion of intact complexes is minimal (<1%). Fecal excretion accounts for less than 1% of the dose.
Ferric carboxymaltose is eliminated primarily via renal excretion of the iron-carbohydrate complex, with approximately 60-70% of the administered iron dose excreted in urine within 24 hours. The remaining 30-40% is retained in the body, incorporated into hemoglobin and iron stores, with minimal biliary or fecal excretion.
Category C
Category C
Iron Replacement
Iron Replacement